Literature DB >> 7310392

Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.

J Balldin, A K Granérus, G Lindstedt, K Modigh, J Wålinder.   

Abstract

The antiparkinsonian effect of electroconvulsive therapy (ECT) was investigated in nine parkinsonian patients with "on-off" phenomena. The patients were maintained on previously adjusted doses of antiparkinsonian drugs during and after ECT. Parkinsonian as well as mental symptoms were rated before and after treatment. Basal serum levels of prolactin (PRL) and growth hormone (GH) as well as apomorphine induced changes (0.24 mg i.v.) in these levels were investigated three days before start of treatment. Marked improvement of parkinsonian symptoms was seen in five patients. Two further patients showed slight improvements. The improvement persisted for 2-41 weeks. Improvement after ECT was found to correlate with age at the time of treatment and with duration of L-dopa therapy as well as the estimated life-dose of L-dopa. No correlation was found between depression before treatment, basal serum levels of GH and PRL or apomorphine induced changes in these hormone levels. The investigation indicates that ECT is a valuable adjuvant in the treatment of a selected group of parkinsonian patients with "on-off" phenomena. Furthermore, the results support our earlier proposal that ECT increases the responsiveness in postsynaptic dopamine sensitive structures.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7310392     DOI: 10.1007/bf01249604

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  25 in total

1.  Experimental studies of the therapeutic action of electroconvulsive therapy in endogenous depression. The role of the electrical stimulation and of the seizure studied by variation of stimulus intensity and modification by lidocaine of seizure discharge.

Authors:  B CRONHOLM; J O OTTOSSON
Journal:  Acta Psychiatr Scand Suppl       Date:  1960

2.  Prognostic factors in the electro-shock treatment of depressive states. II.-The application of specific tests.

Authors:  J M ROBERTS
Journal:  J Ment Sci       Date:  1959-07

3.  Effects of apomorphine and clonidine on rat plasma growth hormone after pretreatment with reserpine and electroconvulsive shocks.

Authors:  S Edén; K Modigh
Journal:  Brain Res       Date:  1977-07-01       Impact factor: 3.252

Review 4.  Recent advances in research on Parkinsonism.

Authors:  U K Rinne
Journal:  Acta Neurol Scand Suppl       Date:  1978

5.  Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome.

Authors:  A K Granerus; G Steg; A Svanborg
Journal:  Acta Med Scand       Date:  1972 Jul-Aug

6.  Drug holidays for patients with parkinsonism.

Authors:  W A Check
Journal:  JAMA       Date:  1979-07-06       Impact factor: 56.272

7.  Effects of electroconvulsive treatment on growth hormone secretion induced by monoamine receptor agonists in reserpine-pretreated rats.

Authors:  J Balldin; P Bolle; S Edén; E Eriksson; K Modigh
Journal:  Psychoneuroendocrinology       Date:  1980-12       Impact factor: 4.905

8.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

Authors:  T Lee; P Seeman; A Rajput; I J Farley; O Hornykiewicz
Journal:  Nature       Date:  1978-05-04       Impact factor: 49.962

9.  Physical training in human hyperplastic obesity. IV. Effects on the hormonal status.

Authors:  P Björntorp; G Holm; B Jacobsson; K Schiller-de-Jounge; P A Lundberg; L Sjöström; U Smith; L Sullivan
Journal:  Metabolism       Date:  1977-03       Impact factor: 8.694

10.  Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.

Authors:  M Quik; E G Spokes; A V Mackay; R Bannister
Journal:  J Neurol Sci       Date:  1979-11       Impact factor: 3.181

View more
  8 in total

1.  Cell implantation in Parkinson's disease.

Authors:  P Madeley; J L Boyd; C A Biggins; R H Mindham; E G Spokes
Journal:  BMJ       Date:  1990-09-15

2.  The psychogeriatrician's view: management of chronic disability in the community.

Authors:  D G Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 3.  Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature.

Authors:  F Fregni; D K Simon; A Wu; A Pascual-Leone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

4.  Elevated dopamine D1 receptor availability in striatum of Göttingen minipigs after electroconvulsive therapy.

Authors:  Anne M Landau; Aage Ko Alstrup; Helene Audrain; Steen Jakobsen; Mette Simonsen; Arne Møller; Poul Videbech; Gregers Wegener; Albert Gjedde; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-16       Impact factor: 6.200

Review 5.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

6.  Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.

Authors:  A Reches; H R Wagner; A I Barkai; V Jackson; E Yablonskaya-Alter; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.

Authors:  J Balldin; A K Granérus; G Lindstedt; K Modigh; J Wålinder
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 8.  Electroconvulsive Therapy and Movement Disorders. New Perspectives on A Time-Tested Therapy.

Authors:  Pedro J Garcia Ruiz
Journal:  Mov Disord Clin Pract       Date:  2021-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.